Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.656
-0.022 (-3.26%)
At close: Nov 20, 2024, 4:00 PM
0.650
-0.006 (-0.93%)
Pre-market: Nov 21, 2024, 7:41 AM EST

Company Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.

It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.

It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.

The company was founded in 2003 and is based in La Jolla, California.

Ensysce Biosciences, Inc.
Ensysce Biosciences logo
Country United States
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 7
CEO D. Kirkpatrick

Contact Details

Address:
7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037
United States
Phone 858 263 4196
Website ensysce.com

Stock Details

Ticker Symbol ENSC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001716947
CUSIP Number 293602108
ISIN Number US2936024056
Employer ID 82-2755287
SIC Code 2834

Key Executives

Name Position
Dr. D. Lynn Kirkpatrick Ph.D. President, Chief Executive Officer and Director
David C. Humphrey CPA Chief Financial Officer, Secretary and Treasurer
Geoffrey Birkett Chief Commercial Officer
Dr. Jeffrey Millard Ph.d. Chief Operating Officer
Dr. William K. Schmidt Ph.D. Chairman of Clinical Advisory Board and Chief Medical Officer
Dr. Linda Pestano Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Nov 19, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 29, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 8-K Current Report
Oct 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 18, 2024 DEF 14A Other definitive proxy statements
Oct 18, 2024 ARS Filing